Lysine and Monolaurin for HSV Suppression: Not Recommended
Lysine and monolaurin should not be used for herpes simplex virus suppression—instead, use proven antiviral medications like acyclovir, valacyclovir, or famciclovir, which reduce recurrence frequency by ≥75%. The evidence for lysine is inconsistent and insufficient, and there is no clinical evidence supporting monolaurin for HSV suppression.
Why Standard Antivirals Are the Clear Choice
All major CDC guidelines from 1993 through 2022 consistently recommend only prescription antiviral medications for HSV suppression 1, 2, 3, 2, 4. These guidelines make no mention of lysine or monolaurin as treatment options, which is telling—if these supplements worked, they would be included.
For daily suppressive therapy, the evidence-based regimens are:
- Acyclovir 400 mg orally twice daily, OR
- Famciclovir 250 mg orally twice daily, OR
- Valacyclovir 500 mg to 1000 mg orally once daily 2
These reduce recurrence frequency by at least 75% in patients with frequent recurrences (≥6 per year) 1, 2, 1, 2, 1.
The Lysine Evidence: Weak and Contradictory
A 2017 systematic review specifically examining lysine for HSV prophylaxis found that lysine supplementation appears ineffective at doses <1 g/day, and only doses exceeding 3 g/day appear to improve subjective patient experience 5. This is critical—most over-the-counter lysine products contain far less than this threshold dose.
The research evidence is all over the map:
- One 1987 study showed benefit with 1000 mg three times daily (3 g/day total), reporting fewer infections and reduced severity 6
- A 1984 study found benefit only when serum lysine exceeded 165 nmol/ml, suggesting prophylactic lysine "may be useful" in selected cases 7
- However, a 1980 double-blind crossover study of 1000 mg daily found no effect on recurrence rate overall, though more patients were recurrence-free during lysine treatment 8
A 2015 Cochrane review found no evidence supporting lysine for HSV prevention 9. This is the highest-quality systematic review available, and it definitively states there is insufficient evidence for lysine efficacy.
The 2017 review concluded that longer duration controlled studies of daily lysine doses exceeding 1.2 g/day are required to definitively test its role, and cautioned that patients with cardiovascular or gallbladder disease should be warned of theoretical risks 5.
Monolaurin: No Clinical Evidence
There is literally no clinical trial evidence for monolaurin in HSV suppression. The only FDA drug label reference shows monolaurin as an ingredient in an acne toner 10—not for herpes treatment. This is a supplement marketed without rigorous clinical validation.
Clinical Algorithm: What to Actually Do
For patients with recurrent HSV (oral or genital):
If ≥6 recurrences per year: Start daily suppressive antiviral therapy
- First choice: Valacyclovir 500 mg once daily (easiest adherence)
- Alternative: Acyclovir 400 mg twice daily or Famciclovir 250 mg twice daily 2
If <6 recurrences per year: Provide episodic therapy prescription to start at first prodrome
- Acyclovir 800 mg twice daily for 5 days, OR
- Valacyclovir 500 mg twice daily for 5 days, OR
- Famciclovir 125 mg twice daily for 5 days 2
After 1 year of suppressive therapy: Reassess and consider discontinuation to evaluate natural recurrence rate 2
HIV-infected patients: Use valacyclovir 500 mg twice daily (not once daily) for adequate suppression 3
Common Pitfalls to Avoid
- Don't recommend lysine as first-line therapy—you're delaying effective treatment and allowing continued recurrences that impact quality of life
- Don't use topical antivirals for suppression—they don't work for prevention and are substantially less effective than oral agents even for treatment 1
- Don't use short-course therapy in HIV patients—they need 5-14 days, not 1-3 day regimens 3
- Don't forget that suppressive therapy doesn't eliminate asymptomatic shedding—counsel patients about transmission risk even on treatment 1, 2, 1, 2
The Bottom Line on Supplements
If a patient insists on trying lysine despite counseling, the evidence suggests only doses ≥3 g/day might provide subjective benefit 5, but this is not a substitute for proven antiviral therapy. There is no role for monolaurin based on current evidence. The FDA-approved lysine products are marketed for topical use on cold sores 11, not for systemic suppression.
Quality of life matters. Recurrent herpes causes pain, cosmetic disfigurement, and psychosocial distress 12, 9. Proven antivirals reduce recurrences by 75%, are well-tolerated with minimal adverse effects 2, 3, and have decades of safety data 2. Don't let patients suffer with ineffective supplements when effective treatment exists.